Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET Primary Endpoint of Safety Met Across all Study GroupsStatistical Significance Met for Secondary Endpoint Composite Alzheimer’s Disease Score (CADS) for Lomecel-B™ Low-Dose and for the Pooled Lomecel-B™ Treatment Group Relative to PlaceboOther Doses Demonstrated Numerical Slowing/Prevention of Disease Worsening Relative to Placebo Additional Biomarker Data Expected to be Announced in the Coming Weeks MIAMI, Oct.

公司今天10月5日上午8:00召开电话会议和网络广播所有研究组的主要安全终点会议Lomecel-B次要终点复合阿尔茨海默病评分（CADS）的统计学意义会议™低剂量和混合Lomecel-B™相对于安慰剂，相对于安慰剂剂量的治疗组显示出疾病恶化的数值减慢/预防。预计将在未来几周内公布额外的生物标志物数据-迈阿密，10月。

05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

052023（GLOBE NEWSWIRE）-Longeveron Inc.（纳斯达克股票代码：LGVN）（“Longeveron”或“Company”），一家临床阶段生物技术公司，为危及生命和慢性衰老相关的疾病开发细胞疗法，如发育不良左心综合征（HLHS），阿尔茨海默病和衰老相关的虚弱，今天宣布其研究产品Lomecel-B的2a期试验取得积极的一线成果™ 用于治疗轻度阿尔茨海默病。

The Company is hosting a conference call and webcast today at 8:00 AM ET to discuss the results. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” said Wa’el Hashad, Chief Executive Officer of Longeveron.

该公司今天上午8:00召开电话会议和网络广播，讨论结果。“我们相信这些结果为Lomecel-B的安全性和治疗潜力提供了重要的验证™Longeveron首席执行官Wa'el Hashad说，该药物可用于治疗阿尔茨海默氏病，并为该适应症和其他适应症的其他临床试验提供坚实的基础。

“We look forward to announcing additional biomarker data from this trial, anticipated to be later this month, which may further characterize the clinical effects of Lomecel-B™ in this study population. With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related Frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully re.

“我们期待从这个试验中公布更多的生物标志物数据，预计将在本月晚些时候公布，这可能进一步表征Lomecel-B的临床效果™在这个研究人群中。随着我们在HLHS进行的第二阶段ELPIS II试验朝着2024年预期完成的方向发展，以及我们在日本与老龄化相关的脆弱性的第二阶段计划也在不断发展，我们期待在近期实现有意义的里程碑并充分恢复。